Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

ebo-controlled trial. Morphotek expects to enroll up to 900 subjects in this clinical study that will be conducted globally at sites in North America, South America, Europe, Australia and Asia.

"Ovarian cancer is a disease that is devastating to the lives of patients and caregivers," said Nicholas Nicolaides, Ph.D., President and Chief Executive Officer at Morphotek. "The agreement reached in the SPA process for farletuzumab's Phase III trial may bring us one step closer to providing hope in their lives and further exemplifies our human health care (hhc) mission to bring treatments to the people who need them most."

Farletuzumab is a monoclonal antibody that binds to and blocks the function of folate receptor alpha (FRA), a cell surface protein on tumor cells that confers a growth advantage to tumorigenic cells in vitro. FRA has been demonstrated by several independent studies to be expressed on ovarian cancer cells. Preclinical data support the theory that farletuzumab achieves its pharmacological effect by two mechanisms: first, by the capacity of farletuzumab to block signaling inside cancer cells and, second, by stimulating the patient's immune system to attack and destroy the FRA positive-tumor cells. The pre-cursor to farletuzumab was originally developed by Dr. Lloyd Old at the Ludwig Institute for Cancer Research applying his pioneering work that employed whole cell immunization of tumors to identify cell surface factors. These efforts led to the development of a panel of novel antibodies that can recognize tumor cell surface antigens as well as tumor stromal cell surface antigens. Morphotek licensed the antibody and improved it using the company's proprietary morphogenics technology.

Ovarian cancer, which ranks fifth as the cause of cancer deaths in women, usually grows asymptomatically before it is discovered. The National Cancer Institute estimates that there were 21,650 new cases of ovarian
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is a ... years. He has recently announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ... 2014. , GoDaddy is a popular supplier of cheap ... hosting solutions at affordable rates. It offers three Linux ... plans depend on the length of the contract. The ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... email marketing services that currently helps more than ... efforts has caught the attention of Shane Michaels, prompting ... still a crucial element for any online marketing campaign, ... replacing email in the marketing world,” reports Michaels. “AWeber ...
(Date:8/22/2014)... Buying a policy for different life insurance products can be ... types by insurers in the U.S. The Quotes Pros company ... public using its sortable tool at http://quotespros.com/life-insurance.html . ... expected to promote the discounts and special offerings for policies ... system is designed to help an adult locate a policy ...
(Date:8/22/2014)... Princeton, Indiana (PRWEB) August 22, 2014 ... because Toyota Indiana is on the grow ... add 300 jobs by summer 2016 to boost production ... expansion will bring Toyota Indiana’s overall investment to $4 ... in North America while providing additional flexibility to adjust ...
(Date:8/22/2014)... August 22, 2014 As the ... http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues to grow, ... companies have decided to limit coverage of uterine ... Telegram, Blue Cross-Blue Shield of Massachusetts will no ... involve morcellation as of September 1, 2014. Other ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4
... 7 CardioFocus, Inc. ( www.cardiofocus.com ) ... allowing the company to commence European marketing of the ... fibrillation. The EAS is the latest generation, percutaneous ... patients with atrial fibrillation. This novel device incorporates ...
... ... , ... July 7, 2009 -- The Texas Hospital Association (THA) has joined ... members to hundreds of career Web sites., , , , ,"HEALTHeCAREERS is proud to ...
... ... (UCC) at the site of its medical office in Glendora, bringing more healthcare options to ... who have urgent but not life-threatening medical needs. , ... Glendora, CA (PRWEB) July 1, 2009-- HealthCare Partners recently opened a ...
... ... Users Location. , ... Plano, TX (PRWEB) July 7, 2009 -- Symon Communications, a global provider of in-venue ... iPhone application following a two week inaugural deployment supporting the Wimbledon tennis tournament in ...
... ... may be able to diagnose deep endometriosis and accurately locate lesions prior to surgery, according ... ... Using magnetic resonance imaging (MRI), radiologists may be able to diagnose deep endometriosis and accurately ...
... ... Web-based patient education service used by medical practices to deliver health information to patients ... ... 2009 -- Vivacare has recently enhanced its Web-based patient education service, providing ...
Cached Medicine News:Health News:CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 2Health News:Texas Hospital Association Endorses HEALTHeCAREERS Network 2Health News:HealthCare Partners Opens Glendora Urgent Care Center 2Health News:HealthCare Partners Opens Glendora Urgent Care Center 3Health News:Symon Announces Revolutionary New Application InView Mobile™ 2Health News:Symon Announces Revolutionary New Application InView Mobile™ 3Health News:MRI Accurately Depicts Deep Endometriosis 2Health News:MRI Accurately Depicts Deep Endometriosis 3Health News:Vivacare Patient Education Service Enhancements Save Medical Practices Time and Money and Improve Patient Satisfaction 2Health News:Vivacare Patient Education Service Enhancements Save Medical Practices Time and Money and Improve Patient Satisfaction 3
(Date:8/22/2014)... 22, 2014 Research ... addition of the  "Global Operating Room Equipment ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating ... environment in a healthcare facility used to ... technically advanced equipment, which ensures patient care ...
(Date:8/22/2014)... On Aug. 20, at its annual meeting in ... voted on and approved a delegate resolution opposing the ... Cannabis Corp., a leading Canadian licensed producer of medicinal ... The CMA is quite right to point out that ... material, including medicinal cannabis. While some patients, particularly those ...
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and Chinese Intravenous Catheter Industry Report 2014" ... and Chinese Intravenous Catheter Industry Report 2014 is a ... the global intravenous catheter industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... , , , PARSIPPANY, N.J., Jan. 11 ... pharmaceutical industry your survival depends on not only what you ... Pharma market research is key. Whoever has the right ... U.S. pharmaceutical industry is the largest (and growing) market in ...
... , ... Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP ... clinical trial of a prototype formulation of its proprietary delayed-release cysteamine ... M.D., Professor of Pediatrics at the University of California, San Diego, ...
Cached Medicine Technology:Elite Pharma Insiders to Reveal Key Survival Strategies for Pharmaceutical Industry in 2010 2Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 2Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 3Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 4Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 5Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 6Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 7
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... Tips offer a safe alternative to using ... for applications such as PCR(a), pipetting radioactive ... Tips are excellent for tissue culture, gel ... Tips prevent aerosol contaminants and liquids from ...
... The Rota-Filler 3000 combines a powerful motor ... adjustable pipet nozzle rotates to three positions ... convenience. Press the nozzle release button on ... the pivot nozzle position. The wide-angle position ...
Medicine Products: